Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 16/20 | 0.42 |
| ▸ | PDE3A | Q14432 | 16/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 16/20 | 0.42 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.40 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.40 |
| ▸ | GBA1 | P04062 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3055217 | 0.94 | PDE3B (0.44) | PDE3BPDE3APDE10ATGFBR1ACVR1 | |
| SCHEMBL3060045 | 0.91 | GBA1 (0.46) | PDE3BPDE3APDE10AGBA1 | |
| SCHEMBL3052708 | 0.90 | PDE10A (0.43) | PDE3BPDE3APDE10AGBA1 | |
| SCHEMBL3051960 | 0.86 | PDE10A (0.51) | PDE3BPDE3APDE10A | |
| SCHEMBL3051678 | 0.86 | PDE10A (0.48) | PDE3BPDE3APDE10A | |
| SCHEMBL3060696 | 0.82 | TGFBR1 (0.44) | PDE3BPDE3APDE10ATGFBR1ACVR1 | |
| SCHEMBL3051849 | 0.80 | PDE10A (0.52) | PDE3BPDE3APDE10A | |
| SCHEMBL3055964 | 0.79 | CHRM2 (0.39) | PDE3APDE10A | |
| SCHEMBL3062929 | 0.79 | CHRM4 (0.43) | PDE3BPDE3APDE10ATGFBR1ACVR1 | |
| SCHEMBL3053175 | 0.79 | LMNA (0.44) | PDE3BPDE3APDE10ATGFBR1ACVR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222353-A1 | AMINOPHTHALAZINE DERIVATIVE COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2010-09-02 | — | — | US | claimed |
| EP-1981868-A2 | AMINOPHTHALAZINE DERIVATIVE COMPOUNDS | Pfizer Products Inc. (US) | 2008-10-22 | — | — | EP | claimed |
| WO-2007085954-A2 | AMINOPHTHALAZINE DERIVATIVE COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2007-08-02 | — | — | WO | claimed |
| US-20100222353-A1 | AMINOPHTHALAZINE DERIVATIVE COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2010-09-02 | — | — | US | disclosed |
| EP-1981868-A2 | AMINOPHTHALAZINE DERIVATIVE COMPOUNDS | Pfizer Products Inc. (US) | 2008-10-22 | — | — | EP | disclosed |
| WO-2007085954-A2 | AMINOPHTHALAZINE DERIVATIVE COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222353-A1 | AMINOPHTHALAZINE DERIVATIVE COMPOUNDS | PDE12, PDE5A, PDE2A | PDE3B 9/4885PDE3A 5/4885PDE10A 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.